Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Vera Therapeutics, Inc. Class A Common Stock

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases that improve patients’ lives.

Vera Therapeutics, Inc.

We’re #hiring! #Joinourteam and take part in our mission to improve the standard of care for patients with serious immunological diseases.
Learn about our open positions here: https://lnkd.in/d2-8KHTC 

Today we announced our Q3 business update and financial results. Read the full release here: https://lnkd.in/df4BxFuY

Dr. Richard Lafayette, MD, FACP, spoke with HCPLive about the additional week 36 analyses from our ORIGIN Phase 2b clinical trial in #IgAN presented at ASN Kidney Week 2023. Watch the interview here: https://lnkd.in/d8eauakC
#kidneywk #IgANephropathy

Today we're presenting two posters with new week 36 analyses from our Phase 2b ORIGIN trial in #IgANephropathy at American Society of Nephrology Kidney Week: https://lnkd.in/dZtKAfQX
Be sure to stop by our posters SA-PO884 and SA-PO887 and visit us at booth 2321! 
#Kidneywk

We’re live at American Society of Nephrology Kidney Week 2023! Come to booth #2321 to learn about our research in #IgANephropathy. And don’t miss our poster presentations on Saturday: https://lnkd.in/dZpvugVK
#kidneywk

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	0.78 -	13.16 1,579.31%	5.93 54.95%	6.99 17.95%	3.76 46.20%
company equity multiplier	-0.15 -	-0.61 314.71%	1.20 297.09%	1.71 42.01%	1.73 1.02%
days of inventory outstanding
days of payables outstanding
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	0.99 -	1.02 3.17%	0.95 7.29%	0.98 3.36%	0.94 3.95%
effective tax rate	-0.00 -	-0.00 77.81%	-0.00 63.80%	-0.00 63.38%	0.00 192.78%
enterprise value multiple	-3.97 -	0.14 103.41%	-8.26 6,198.63%	-4.74 42.65%	-5.39 13.73%
fixed asset turnover
free cash flow per share	-2.55 -	-8.56 235.20%	-1.76 79.39%	-2.55 44.31%
gross profit margin
interest coverage	-234.53 -	-314.70 34.19%	-1.72K 446.58%	-91.64 94.67%
inventory turnover
long term debt to capitalization	-0.00 -		0.07 -	0.27 310.72%	0.33 21.28%
net income per ebt	1.00 -	1.00 0.01%	1.00 0.00%	1.00 0.00%	1.00 0.00%
net profit margin
operating cash flow per share	-2.52 -	-8.54 238.31%	-1.76 79.34%	-2.54 44.17%
operating profit margin
payables turnover
pretax profit margin
price fair value	-1.28 -	-0.52 59.09%	5.16 1,083.23%	6.69 29.59%	6.46 3.38%
receivables turnover
return on assets	-2.20 -	-0.98 55.56%	-0.39 60.23%	-0.68 74.02%	-0.55 19.30%
return on capital employed	-2.77 -	-1.00 63.81%	-0.45 54.85%	-0.86 89.89%	-0.67 22.50%
return on equity	0.32 -	0.60 84.32%	-0.47 178.38%	-1.16 147.12%	-0.94 18.48%
total debt to capitalization	-0.00 -	-0.00 99.38%	0.07 295,242.16%	0.29 337.68%	0.34 17.48%

COM:VERATX

Vera Therapeutics, Inc.

Last Close

47.03

22/11 21:00

Market Cap

3.06B

Beta: -

Volume Today

793.05K

Avg: -

Preview